Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease
Phase IIa 20 Week Double-blind, Placebo-controlled, Randomized, Escalating Dose Study to Evaluate the Safety and Tolerability of Four Oral Doses of NP031112, a Novel GSK3 Inhibitor, in Mild to Moderate Alzheimer's Disease Patients With Stable Anticholinesterasic Treatment.
Sponsor: Noscira SA
A PHASE1/PHASE2 clinical study on Alzheimer´s Disease, this trial is completed. The trial is conducted by Noscira SA and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Noscira SA
For direct contact, visit the study record on ClinicalTrials.gov .